Orton Armstrong, MD
Internal Medicine · Parkersburg, WVNPI 1871550947
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,184 of the $9,115 with a category attached, or 78.8%. 33 manufacturers reported payments, led by AbbVie at 44.3% of the total. Reporting peaked in 2022 at $3,259 and has fallen 72.1% since, to $910 in 2025. Among internal medicine clinicians in WV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 426 payments — averaging $21.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$4K
- AstraZeneca$700
- Corium, LLC$613
- Ironshore Pharmaceuticals Inc.$386
- Novo Nordisk$309
- Pfizer$306
- plus $3K from 27 others
What the payments were for
- Speaking & faculty fees$1,92521%
- Food & beverage$7,18479%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 131 | $4,041 |
| AstraZeneca | 30 | $700 |
| Corium, LLC | 37 | $613 |
| Ironshore Pharmaceuticals Inc. | 22 | $386 |
| Novo Nordisk | 23 | $309 |
| Pfizer | 18 | $306 |
| Amarin Pharma, Inc. | 14 | $277 |
| Merck | 16 | $266 |
| Neos Therapeutics, LP | 16 | $255 |
| Lilly USA, LLC | 17 | $248 |
| Sanofi-aventis U.S. LLC | 14 | $213 |
| Exact Sciences | 9 | $199 |
| Biohaven Pharmaceutical Holding Company Ltd. | 12 | $154 |
| Sanofi Pasteur Inc. | 7 | $150 |
| GSK | 9 | $147 |
| Sumitomo Pharma America, Inc. | 5 | $111 |
| Biohaven Pharmaceuticals, Inc. | 5 | $87 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $86 |
| Xeris Pharmaceuticals, Inc. | 4 | $76 |
| Johnson & Johnson | 4 | $72 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $67 |
| Supernus Pharmaceuticals, Inc. | 4 | $61 |
| Avanir Pharmaceuticals, Inc. | 3 | $57 |
| Boehringer Ingelheim | 4 | $56 |
| Novartis | 3 | $43 |
| Otsuka America Pharmaceutical, Inc. | 2 | $30 |
| Corcept Therapeutics | 1 | $22 |
| Ultragenyx Pharmaceutical Inc. | 1 | $18 |
| Phadia US Inc. | 1 | $16 |
| Tris Pharma Inc | 1 | $13 |
| Eisai Inc. | 1 | $12 |
| Adlon Therapeutics L.p. | 1 | $12 |
| Aytu Biopharma, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,115 in reported general payments places this provider in the 95th percentile of 573 internal medicine providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 182 | $119,600 |
| JardianceEmpagliflozin | 23 | $29,734 |
| OzempicSemaglutide | 27 | $28,935 |
| MounjaroTirzepatide | 22 | $27,815 |
| Atorvastatin Calcium | 359 | $2,590 |
| Rosuvastatin Calcium | 196 | $1,905 |
| Levothyroxine Sodium | 216 | $1,821 |
| Metoprolol Succinate | 158 | $1,673 |
| Omeprazole | 164 | $1,649 |
| Ezetimibe | 98 | $1,546 |
| Escitalopram Oxalate | 131 | $1,438 |
| Pantoprazole Sodium | 134 | $1,297 |
| Olmesartan Medoxomil | 85 | $1,243 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 19 | $1,236 |
| SynthroidLevothyroxine Sodium | 36 | $1,189 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $306 | $119,600182 claims |
| Boehringer IngelheimJardiance | $56 | $29,73423 claims |
| Novo NordiskOzempic | $309 | $28,93527 claims |
| Lilly USA, LLCMounjaro | $248 | $27,81522 claims |
| AbbVieSynthroid | $4,041 | $1,18936 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 573 internal medicine providers in West Virginia.
Other internal medicine in Parkersburg
- David PickeringParkersburg$599K
- Jennifer LeavittParkersburg$8K
- William TomlinsonParkersburg$7K
- Joan AllmanParkersburg$5K
- William ChapmanCharleston$1.7M
- Govind PatelFairmont$59K
- Bisher MustafaHuntington$28K
- Johny AlencherryMartinsburg$27K
- Ali KhanBuckhannon$21K
- Joseph HashemBerkeley Springs$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.